KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Assets (2016 - 2025)

Fulgent Genetics' Assets history spans 10 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Assets fell 0.53% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 0.53%, while the annual FY2025 figure was $1.2 billion, 0.53% down from the prior year.
  • Assets for Q4 2025 was $1.2 billion at Fulgent Genetics, roughly flat from $1.2 billion in the prior quarter.
  • Across five years, Assets topped out at $1.5 billion in Q1 2022 and bottomed at $999.1 million in Q1 2021.
  • The 5-year median for Assets is $1.2 billion (2024), against an average of $1.3 billion.
  • The largest annual shift saw Assets surged 1018.48% in 2021 before it fell 10.87% in 2023.
  • A 5-year view of Assets shows it stood at $1.3 billion in 2021, then rose by 8.39% to $1.4 billion in 2022, then dropped by 10.87% to $1.2 billion in 2023, then dropped by 1.24% to $1.2 billion in 2024, then decreased by 0.53% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Assets are $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).